Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
• Effective diagnostic biomarkers and therapeutic targets for HCC are lacking.
• Novel molecular targets are crucial for developing new therapeutic strategies.

Purpose of the Study:

• To investigate the role of diacylglycerol acyltransferase 2 (Dgat2) in HCC.
• To evaluate Dgat2 as a potential diagnostic biomarker and therapeutic target for HCC.

Main Methods:

• Comparison of Dgat2 expression in human HCC tissues versus matched normal tissues.
• Assessment of the correlation between Dgat2 expression and patient survival.
• In vitro studies on HCC cell proliferation upon Dgat2 overexpression.
• In vivo tumor growth studies in Balb/c nude mice using HCC cells with Dgat2 overexpression.
• Analysis of cell cycle-related gene expression in HCC cells overexpressing Dgat2.

Main Results:

• Dgat2 expression was significantly downregulated in human HCC tissues.
• High Dgat2 expression correlated with significantly longer patient survival.
• Overexpression of Dgat2 suppressed HCC cell proliferation in vitro.
• Tumor weight and volume were markedly reduced in vivo in mice bearing HCC cells overexpressing Dgat2.
• Cell cycle-related gene expression was downregulated in HCC cells overexpressing Dgat2.

Conclusions:

• Dgat2 plays a significant role in regulating HCC cell proliferation.
• Dgat2 functions as a potential tumor suppressor in HCC.
• Dgat2 represents a promising anticancer target and diagnostic biomarker for HCC.